Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun An
anticancer agent obtained from thebacterium Chromobacterium violaceum
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word romidepsin.
Examples
-
With the new test in hand, the team profiled the potency of 16 widely used HDAC inhibitors, including many clinical candidates and two FDA-approved drugs, SAHA and romidepsin, against nine HDACs.
PhysOrg.com - latest science and technology news stories 2010
-
With the new test in hand, the team profiled the potency of 16 widely used HDAC inhibitors, including many clinical candidates and two FDA-approved drugs, SAHA and romidepsin, against nine HDACs.
PhysOrg.com - latest science and technology news stories 2010
-
Kamada commences enrollment in European inhaled AAT clinical trial for alpha-1 antitrypsin deficiency Gloucester's romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee
THE MEDICAL NEWS Editors 2010
-
With the new test in hand, the team profiled the potency of 16 widely used HDAC inhibitors, including many clinical candidates and two FDA-approved drugs, SAHA and romidepsin, against nine HDACs.
PhysOrg.com - latest science and technology news stories 2010
-
The U.S. Food and Drug Administration has approved Istodax (romidepsin), an injectable medication, f ...
THE MEDICAL NEWS 2010
-
Kamada commences enrollment in European inhaled AAT clinical trial for alpha-1 antitrypsin deficiency Gloucester's romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee
THE MEDICAL NEWS Editors 2010
-
Gloucester Pharmaceuticals raises funds for the development of romidepsin
THE MEDICAL NEWS 2010
-
With the new test in hand, the team profiled the potency of 16 widely used HDAC inhibitors, including many clinical candidates and two FDA-approved drugs, SAHA and romidepsin, against nine HDACs.
PhysOrg.com - latest science and technology news stories 2010
-
- (Business Wire) - May 28, 2009 - Gloucester Pharmaceuticals today announced that results from two studies of romidepsin, its novel, cyclic peptide, histone deacetylase inhibitor under investigation for the treatment of hematologic malignancies, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida on Saturday, May 30, 2009.
-
Poster S13 #8584 entitled "Histone deacetylase inhibitors potently synergize the antineoplastic effects of the proteasome inhibitor bortezomib in mantle cell lymphoma (MCL)" by L Paoluzzi, L Scotto, Seshan and O O'Connor, describes data from a preclinical study of romidepsin in combination with Velcade® (bortezomib) in mantle cell lymphoma (MCL).
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.